STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Inclusion Criteria: Main phase:

• Male or female, age greater than or equal to 18 years at the time of signing informedconsent
• Body mass index (BMI) greater than or equal to 30.0 kg/sqm or greater than or equal to 27.0 kg/sqm with the presence of at least one of the following weight-relatedcomorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleepapnoea or cardiovascular disease
• History of at least one self-reported unsuccessful dietary effort to lose body weight Extension phase:
• Informed consent for the extension phase obtained before any trial related activitiesfor the extension phase
• On randomised treatment on the target dose at week 68, i.e. treated with 2.4 mgsemaglutide once-weekly or semaglutide placebo

Exclusion Criteria: Main phase:

• Glycated haemoglobin (HbA1C) greater than or equal to 48 mmol/mol (6.5%) as measuredby the central laboratory at screening
• A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days beforescreening irrespective of medical records Extension phase:
• Female who is pregnant or intends to become pregnant during the extension phase
• Any disorder, unwillingness or inability, not covered by any of the other exclusioncriteria, which in the investigator's opinion, might jeopardise the subject'scompliance with the extension of the trial